SEC Form 4 · accession 0002018150-26-000003
Traws Pharma, Inc. · TRAW
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles David Pauza
Officer — Chief Science Officer Virology
Period of report
Jul 9, 2026
Accepted (ET)
Jul 16, 2026 · 12:39 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001130598
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.68 | Jul 9, 2026 | A | 97,000 | A | Jul 9, 2027 | Jul 9, 2036 | Common Stock | 97,000 | 97,000 | D |
Explanation of responses
- F1Represents stock options awarded by the Issuer's compensation committee (comprised of independent directors) to the reporting person under the Issuer's 2021 Incentive Compensation Plan, as amended and/or restated through the date hereof. The stock options under this award will vest 100% on the first anniversary of the grant date.